Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lymphoid Cells and Tissues01:18

Lymphoid Cells and Tissues

1.2K
Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
1.2K
Lymphatic Vessels and Lymph Transport01:16

Lymphatic Vessels and Lymph Transport

3.7K
Lymphatic vessels, known as lymphatics, are crucial in transporting lymph from peripheral tissues to our venous system. This process begins with lymph entering through tiny capillaries that branch through tissues. These capillaries have unique features such as larger diameters, thinner walls, and a distinctive one-way valve system formed by overlapping endothelial cells.
This one-way system allows fluids, solutes, and even pathogens to enter but prevents their return to the intercellular...
3.7K
Primary Lymphoid Organs01:16

Primary Lymphoid Organs

1.6K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
1.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Secondary Lymphoid Organs01:15

Secondary Lymphoid Organs

1.6K
Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Australasian chronic lymphocytic leukaemia consensus statement: 2026 update.

Internal medicine journal·2026
Same author

High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Indirect Comparison of the Efficacy of Zanubrutinib vs Ibrutinib and Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-Up.

Advances in therapy·2026
Same author

Obinutuzumab, lenalidomide, and venetoclax for the initial treatment of patients with advanced-stage follicular lymphoma: Results of the Phase Ib/II LEVERAGE study.

HemaSphere·2026
Same author

USP2 is an androgen-repressed survival factor that stabilises oncoproteins to facilitate therapy resistance in prostate cancer.

Cell death & disease·2026
Same author

Australian clinical practice guideline: diagnosis and treatment of idiopathic multicentric Castleman disease.

Internal medicine journal·2026

Related Experiment Video

Updated: Jul 15, 2025

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

21.2K

Chronic lymphocytic leukaemia Australasian consensus practice statement.

Mary A Anderson1,2,3, Rory Bennett1, Xavier Badoux4

  • 1Department of Clinical Haematology, The Royal Melbourne Hospital and The Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

Internal Medicine Journal
|September 24, 2023
PubMed
Summary
This summary is machine-generated.

This consensus statement provides updated guidance for chronic lymphocytic leukaemia (CLL) management in Australia and New Zealand. It incorporates advances in diagnostics, novel therapies like BTKi and BCL2 inhibitors, and pandemic considerations for haematologists.

Keywords:
CLLconsensusdiagnosismanagement

More Related Videos

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

13.8K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.4K

Related Experiment Videos

Last Updated: Jul 15, 2025

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

21.2K
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

13.8K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.4K

Area of Science:

  • Haematology
  • Oncology
  • Medical Practice

Background:

  • Chronic lymphocytic leukaemia (CLL) is the most prevalent haematological malignancy in Australia and New Zealand (ANZ).
  • Recent advancements in diagnostic tools, including next-generation sequencing and measurable residual disease assessment, have significantly impacted CLL prognostication and response evaluation.
  • The therapeutic landscape for CLL has been revolutionized by novel agents such as Bruton's tyrosine kinase (BTKi) and BCL2 inhibitors.

Purpose of the Study:

  • To provide standardized, Australasian-specific guidance for the investigation and management of CLL.
  • To address the evolving diagnostic and treatment paradigms in CLL.
  • To offer recommendations on supportive care and special considerations, including during the COVID-19 pandemic.

Main Methods:

  • Development of a consensus practice statement by a multidisciplinary group of ANZ CLL experts.
  • Endorsement by peak haematology bodies within the Australasia region.
  • Review and synthesis of current evidence and clinical experience in CLL management.

Main Results:

  • The statement integrates new diagnostic technologies for improved prognostication.
  • It details the application of novel therapies (BTKi, BCL2 inhibitors) for various CLL patient groups.
  • Guidance is provided on supportive care and managing CLL in the context of the SARS-CoV-2 pandemic.

Conclusions:

  • This consensus provides essential, localized guidance for Australian and New Zealand clinicians managing CLL.
  • The recommendations reflect the latest advancements in CLL diagnostics and therapeutics.
  • Standardized management strategies are crucial given the unique healthcare environment in Australasia.